Medtronic Lays Out Plans To Achieve 5%+ Annual Growth
The medtech giant offered additional details on its ongoing restructuring plan intended to make the company more competitive.
You may also be interested in...
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the first day of the meeting.
Sean Salmon, the head of Medtronic’s diabetes business, will take over the leadership of the company’s cardiovascular business effective 1 January.
Ai Biomed’s PTeye helps to identify parathyroid tissue during thyroid surgery. Medtronic ENT also announced the FDA clearance of its NIM Vital electromyographic system for nerve monitoring during surgery.